Home Edwards Lifesciences Corporation

Edwards Lifesciences Corporation

Edwards SAPIEN 3 Transcatheter Heart Valve Receives Approval In China

SAPIEN 3 transcatheter heart valve builds on Edwards' decades of experience in the development of tissue heart valves, and the proven benefits of the Edwards SAPIEN transcatheter heart valves.

PASCAL PASCAL Transcatheter Valve Repair System Receives European Approval For Tricuspid Repair

The PASCAL system is indicated in Europe for the percutaneous reconstruction of the tricuspid valve through leaflet repair by tissue approximation.

5/7/19: Results of the COMMENCE Clinical Study Show a Favorable Outcome: Data Presented at AATS

The data shows that Edwards' bioprosthetic surgical aortic valves featuring the company's novel RESILIA tissue platform continued to demonstrate favorable safety and hemodynamic performance through a median of four years follow-up, with no events of structural valve deterioration (SVD). The COMMENCE study enrolled 694 patients, 144 (21 percent) of which were under the age of 60 when they had surgical valve replacement. The data were presented at the American Association for Thoracic Surgery's (AATS) 99th annual meeting.

Edwards Lifesciences Enters Into Agreement To Acquire CASMED

2/19/19: Edwards will acquire CASMED in an all-cash transaction for $2.45 per share of Common Stock, or an equity value of approximately $100 million.

Commencement of U.S. Study of Self-Expanding Transcatheter Heart Valve Reports Edwards Life Sciences

10/9/18: The prospective, single-arm, multi-center study is expected to enroll approximately 1,000 patients and includes a bicuspid registry. The study has a composite endpoint of all-cause death and/or all stroke at 1 year reports the company.

Edwards Life Sciences Comments On CMS Initiation Of National Coverage Analysis For TAVR

6/28/18: CMS announced that it has opened the NCA to reconsider the National Coverage Determination (NCD) released in 2012 for TAVR. This development was clearly expected and the analysis will examine the extensive body of evidence regarding the clinical, economic and quality of life benefits of TAVR.